The FDA has approved a second oral rotavirus vaccine, called Rotarix, which is in liquid form and is given in a two-dose series to infants of 6 to 24 weeks of age. The rotavirus infection results in vomiting and diarrhea in children. The new vaccine provides protection against the G1, G3, G4, and G9 strains, which cause rotavirus gastroenteritis. The vaccine is manufactured by GlaxoSmithKline Biologicals, of Rixensart, Belgium.